跳至主要内容
临床试验/EUCTR2011-002739-24-DK
EUCTR2011-002739-24-DK进行中(未招募)不适用

Does the GLP-1 receptor agonist (Victoza®) improve the metabolic response to physical training in patients with type 2 diabetes?

Dr. med. Tina Vilsbøll0 个研究点开始时间: 2011年8月26日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Informed oral and written consent
  • Diagnosed with type 2 diabetes according to the criteria of the WHO
  • (see appendix 5)
  • HbA1C: 7-10% (doing treatment with diet and/or metformin)
  • Age >18 years
  • BMI >25 kg/m2 <35 kg/m2
  • Negative islet cell antibodies (ICA) and glutamatsyre decarboxylase 65
  • (GAD-65) autoantibodies
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • Females of child bearing potential who are pregnant, breast-feeding or
  • have intention of becoming pregnant or are not using adequate
  • contraceptive measures.
  • Subjects treated with sulfonylurinstof, dipeptidyl peptidase 4 (DPP-4)
  • inhibitors, insulin or glitazoner
  • Ongoing abuse of alcohol or narcotics
  • Impaired hepatic function (liver transaminases >2 times upper normal
  • Impaired renal function (se-creatinine >150µM and/or albuminuria)
  • XML File Identifier: POxD9P5KKuNPnWUv/kBDFfkMsD0=
  • Cardic problems defined as decompensated heart failure (NYHA class
  • III or IV), unstable angina pectoris and/or myocardial infarction within
  • the last 12 months (see appendix 6)
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg,
  • diastolic blood pressure >100 mmHg)
  • Any condition that the investigators feels would interfere with trial
  • participation
  • Receiving any investigational drug within the last 3 months
  • Compliance <80% to training

研究者

发起方
Dr. med. Tina Vilsbøll

相似试验